跳至主要内容
临床试验/NCT03267134
NCT03267134已完成不适用

The Hydrus Microstent for Refractory Open-Angle Glaucoma: A Prospective, Multicenter Clinical Trial (Hydrus VII Study)

Ivantis, Inc.20 个研究点 分布在 5 个国家目标入组 217 人开始时间: 2017年8月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
Ivantis, Inc.
入组人数
217
试验地点
20
主要终点
Percentage of Subjects With Greater Than or Equal to a 20 Percent Decrease From Baseline in Mean Diurnal Intraocular Pressure (MDIOP) at Month 12 While Maintaining the Same or Fewer Number of Medications as at Baseline

研究概览

简要总结

The purpose of this study is to assess the safety and effectiveness of the Hydrus Microstent in patients with refractory open-angle glaucoma.

详细描述

Participants will attend a screening visit, a baseline visit, a surgery visit, and 8 post-operative visits (Day 1, Day 7, Month 1, Month 2, Month 3, Month 6, Month 9, Month 12), for a total individual duration of approximately 14 months.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
45 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Open-angle glaucoma with optic nerve pathology;
  • BCVA of 20/80 or better in study eye;
  • Refractory glaucoma;
  • Other protocol-specified inclusion criteria may apply.

排除标准

  • Secondary glaucoma other than pseudoexfoliative and pigmentary glaucoma;
  • Acute angle closure, chronic angle closure, or congenial, malignant, or developmental glaucoma;
  • Pre-perimetric glaucoma;
  • Ocular hypertension
  • Shallow or flat anterior chamber;
  • Other protocol-specified exclusion criteria may apply.

研究组 & 干预措施

Hydrus Microstent

Experimental

Hydrus Microstent implanted in the eye per the supplied Hydrus Microstent Instructions for Use and associated training. Only one eye (study eye) will be implanted.

干预措施: Hydrus Microstent (Device)

Hydrus Microstent

Experimental

Hydrus Microstent implanted in the eye per the supplied Hydrus Microstent Instructions for Use and associated training. Only one eye (study eye) will be implanted.

干预措施: Ophthalmic surgery (Procedure)

结局指标

主要结局

Percentage of Subjects With Greater Than or Equal to a 20 Percent Decrease From Baseline in Mean Diurnal Intraocular Pressure (MDIOP) at Month 12 While Maintaining the Same or Fewer Number of Medications as at Baseline

时间窗: Baseline, Month 12

Intraocular pressure was measured using Goldmann Applanation tonometry. Three separate IOP measurements were taken over an 8-hour period and averaged together to achieve mean diurnal intraocular pressure.

次要结局

  • Mean Change From Baseline in MDIOP at Month 12(Baseline, Month 12)

研究者

发起方
Ivantis, Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (20)

Loading locations...

相似试验